Stefan Ryser

Dr. Ryser has held senior management positions of increasing responsibility at F. Hoffmann-La Roche, ending as Chief of Staff for the President of Global Research and Development, Dr. Juergen Drews, operating out of both Nutley, NJ and Basel, Switzerland. While at Roche, he led initiatives to assess the impact of emerging technologies on pharmaceutical research and development, and assisted in establishment and management of strategic research and development alliances. He was a member of the joint steering committee with Millennium Pharmaceuticals and a liaison for new research projects with Genentech. In 1998, he founded International Biomedicine Partners with Juergen Drews, a biotech fund whose IPO successes led to him becoming managing partner in 2000 of Bear Stearns Health Innoventures, a $212 million private equity fund.

Dr. Ryser has served on numerous boards of directors in both public and private biotechnology companies, including Arena Pharmaceuticals, Achillion Pharmaceuticals, Entelos, Raven Biotechnologies, Tolerx, and Telik, as well as in the R. Geigy Foundation, a philanthropic organization that supports the Swiss Tropical Institute in Basel. Prior to joining Trellis Bioscience, Dr. Ryser was CEO at A-Cube (now part of Trellis), a biotech company focused on identifying B-cell epitopes. Prior to A-Cube he was SVP for corporate strategy at Telik, and VP of Business Development at Aridis Pharmaceuticals, a leading infectious disease company. Dr. Ryser earned his undergraduate degree in molecular biology and biochemistry and his Ph.D. in immunology at the University of Basel’s Institute for Immunology.